Evotec SE (EVO) Capital Leases (2009 - 2022)

Evotec SE (EVO) posted Capital Leases of -$152437.6 for Q2 2022, up 1.99% sequentially from -$155538.9 in Q4 2021.

Evotec SE (EVO) Capital Leases (2009 - 2022) Analysis & Trends

Evotec SE has reported Capital Leases for 4 years, with the latest figure at -$152437.6 in Q2 2022.

Quarterly Capital Leases changed N/A year-over-year to -$152437.6 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was -$152437.6 (changed N/A YoY) and the FY2021 annual result came in at -$155538.9, changed N/A from the prior year.
Capital Leases rose to -$152437.6 in Q2 2022 per EVO's latest filing, from -$155538.9 in the prior quarter.
Over five years, Capital Leases peaked at -$152437.6 in Q2 2022 and troughed at -$155538.9 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	44.11 Bn	43.15 Bn	-
2	Teva Pharmaceutical Industries	43.24 Bn	39.59 Bn	2.15 Bn
3	Zoetis	31.84 Bn	30.17 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.58 Bn	22.78 Bn	5.10 Bn
5	United Therapeutics	22.44 Bn	19.78 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn
8	Elanco Animal Health	12.03 Bn	11.50 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.06 Bn	9.89 Bn	-
10	Evotec SE	700.45 Mn	699.97 Mn	-

Download Data